Elliptio complanata
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA194430 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Elliptio complanata Transcriptome or Gene expression
| PRJNA575711 | ENA
Project description:Differential gene expression of Elliptio complanata in response to sodium chloride
| PRJNA395103 | ENA
Project description:Metatranscriptome from Millepora complanata
| PRJNA524360 | ENA
Project description:The complete chloroplast genome of Phyllophyton complanatum
| PRJNA728809 | ENA
Project description:<p>Bibenzyls are a specialized metabolite class found throughout the plant kingdom. One of the most prolific producers of bibenzyls are liverworts, specifically plants of the <em>Radula</em> genera. These plants possess an incredible diversity of bibenzyls, prenylated bibenzyls and a few (bis)bibenzyls, several of which have medicinal properties, including perrottetinene, an analog of tetrahydrocannabinol from cannabis. To provide insight into the bibenzyls’ biosynthesis <em>in planta</em>, exogenous phytohormones were applied to <em>in vitro</em> grown <em>Radula complanata</em> and bibenzyl metabolite production was monitored with targeted and untargeted metabolomics. The targeted metabolomic analysis of six prenylated bibenzyls revealed that production of these metabolites was largely reduced when plants were treated with abscisic acid (AA), salicylic acid (SA), 1-naphthaleneacetic acid (NAA) or 6-benzylaminopurine (BAP). The reduction of these metabolites in the BAP and NAA treatment suggests that prenylated bibenzyl production is negatively correlated with vegetative plant growth. The reduction of bibenzyls at low AA and SA concentrations and mild increase at higher AA and SA concentrations suggest that their production is regulated by these stress hormones. In addition, six other bibenzyl metabolites were tentatively identified from the untargeted analysis. These results provide insight into the influence of phytohormones on the bioactive bibenzyl content of <em>R. complanata</em>.</p><p><br></p><p><strong>Targeted metabolomics </strong>is reported in the current study <a href='https://www.ebi.ac.uk/metabolights/MTBLS4321' rel='noopener noreferrer' target='_blank'><strong>MTBLS4321</strong></a>.</p><p><strong>Untargeted metabolomics</strong> is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS3563' rel='noopener noreferrer' target='_blank'><strong>MTBLS3563</strong></a>.</p>
2024-01-10 | MTBLS4321 | MetaboLights
Project description:<p>Bibenzyls are a specialized metabolite class found throughout the plant kingdom. One of the most prolific producers of bibenzyls are liverworts, specifically plants of the <em>Radula</em> genera. These plants possess an incredible diversity of bibenzyls, prenylated bibenzyls and a few (bis)bibenzyls, several of which have medicinal properties, including perrottetinene, an analog of tetrahydrocannabinol from cannabis. To provide insight into the bibenzyls’ biosynthesis <em>in planta</em>, exogenous phytohormones were applied to <em>in vitro</em> grown <em>Radula complanata</em> and bibenzyl metabolite production was monitored with targeted and untargeted metabolomics. The targeted metabolomic analysis of six prenylated bibenzyls revealed that production of these metabolites was largely reduced when plants were treated with abscisic acid (AA), salicylic acid (SA), 1-naphthaleneacetic acid (NAA) or 6-benzylaminopurine (BAP). The reduction of these metabolites in the BAP and NAA treatment suggests that prenylated bibenzyl production is negatively correlated with vegetative plant growth. The reduction of bibenzyls at low AA and SA concentrations and mild increase at higher AA and SA concentrations suggest that their production is regulated by these stress hormones. In addition, six other bibenzyl metabolites were tentatively identified from the untargeted analysis. These results provide insight into the influence of phytohormones on the bioactive bibenzyl content of <em>R. complanata</em>.</p><p><br></p><p><strong>Untargeted metabolomics</strong> is reported in the current study <a href='https://www.ebi.ac.uk/metabolights/MTBLS3563' rel='noopener noreferrer' target='_blank'><strong>MTBLS3563</strong></a>.</p><p><strong>Targeted metabolomics</strong> is reported in <a href='https://www.ebi.ac.uk/metabolights/MTBLS4321' rel='noopener noreferrer' target='_blank'><strong>MTBLS4321</strong></a>.</p>
2024-01-10 | MTBLS3563 | MetaboLights
Project description:Interventions: A group:Before using cetuximab;B group:After progression of disease:no
Primary outcome(s): KRAS gene sequence;NRAS gene sequence;BRAF gene sequence;PIK3CA gene sequence;EGFR gene sequence;EGFR gene copy numbers;EGFR expression;Her2 expression;c-Met expression;PTEN expression
Study Design: historical control
| 2671639 | ecrin-mdr-crc